Cyclocytidine chemotherapy for malignant melanoma.
Twenty-nine patients with metastatic malignant melanoma were treated with cyclocytidine, 240 mg/m2/day sc for 10 days. All partients had received extensive prior chemotherapy. Only one patient achieved a partial remission; the overall response rate (complete plus partial) was 4%. Unusual toxic effects associated with cyclocytidine chemotherapy included the delayed onset of thrombocytopenia, orthostatic hypotension, and jaw pain.
D003504:Ancitabine / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003561:Cytarabine / Q000031:analogs & derivatives*; D006801:Humans; D008545:Melanoma / Q000188:drug therapy*; D009362:Neoplasm Metastasis
D003561:Cytarabine; D003504:Ancitabine